EMA/517240/2018

European Medicines Agency decision

P/0284/2018

of 12 September 2018

on the agreement of a paediatric investigation plan for human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400), (EMEA-002185-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0284/2018

of 12 September 2018

on the agreement of a paediatric investigation plan for human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400), (EMEA-002185-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Taiga Biotechnologies, Inc. on 6 September 2017 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 July 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400), dispersion for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Taiga Biotechnologies, Inc, 12635, East Montview Boulevard, 80045-7336, Aurora, United States.

EMA/PDCO/304098/2018
London, 27 July 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-002185-PIP02-17

Scope of the application

Active substance(s):

Human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400)

Condition(s):

Treatment in haematopoietic stem cell transplantation in patients with severe combined immunodeficiency syndrome (SCID)

Pharmaceutical form(s):

Dispersion for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Taiga Biotechnologies, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Taiga Biotechnologies, Inc. submitted for agreement to the European Medicines Agency on 6 September 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 17 October 2017.

Supplementary information was provided by the applicant on 1 May 2018. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a deferral.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment in haematopoietic stem cell transplantation in patients with severe combined immunodeficiency syndrome (SCID)

2.1.1. Indication(s) targeted by the PIP

Treatment in haematopoietic stem cell transplantation in paediatric patients with SCID

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Determination of human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400) stability for 72 hours
Non-clinical studies	0	Not applicable
Clinical studies	2	**Study 2 (TBX-1400-001)** Open-label, uncontrolled trial to evaluate safety and activity of TBX-1400 in children from 1 month to less than 5 years of age with severe combined immunodeficiency (SCID) **Study 3 (TBX-1400-002)** Double-blind, randomised, controlled trial to evaluate safety and efficacy of TBX-1400 compared to standard of care haematopoietic stem cell transplantation in children from birth to less than 18 years of age with SCID

Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2029
Deferral for one or more measures contained in the paediatric investigation plan:	No